Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.

Eric Jonasch,Giuseppe Procopio,Robert E. Hawkins,Ángel Rodríguez Sánchez,S. Vázquez,Narayanan Srihari,Haralabos P. Kalofonos,Aristotelis Bamias,Petri Bono,Chaitali Babanrao Pisal,Yulia Hirschberg,Luca Dezzani,Qasim Ahmad,Manuela Schmidinger

Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.

2018

Eric Jonasch
Giuseppe Procopio
Robert E. Hawkins
Ángel Rodríguez Sánchez
S. Vázquez
Narayanan Srihari
Haralabos P. Kalofonos
Aristotelis Bamias
Petri Bono
Chaitali Babanrao Pisal
Yulia Hirschberg
Luca Dezzani
Qasim Ahmad
Manuela Schmidinger

4561Background: Although pazopanib (PAZ) has been evaluated in clinical trials of patients (pts) with renal cell carcinoma (RCC), limited real-world data on the effectiveness and safety of PAZ exis...

Keywords:

Clinical trial
Pazopanib
Physical therapy
Renal cell carcinoma
Medicine
first line
Oncology
Internal medicine
Pathology
non clinical

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations